MEMP1972A

DRUG3 trials

Sponsors

Genentech, Inc.

Conditions

Allergic RhinitisAsthma

Phase 1

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of MEMP1972A in Patients With Allergic Rhinitis

CompletedNCT01160861

Genentech, Inc.Allergic Rhinitis

Start: 2010-07-11End: 2011-04-30Updated: 2022-12-12

Phase 2

A Study of MEMP1972A in the Prevention of Allergen-Induced Airway Obstruction in Patients With Mild Asthma (SOLARIO)

CompletedNCT01196039

Genentech, Inc.Asthma

Start: 2010-12-31End: 2012-01-31Updated: 2016-11-02

A Study of MEMP1972A in Patients With Allergic Asthma Inadequately Controlled on Inhaled Steroids And A Second Controller (COSTA)

CompletedNCT01582503

Genentech, Inc.Asthma

Start: 2012-04-30End: 2014-11-30Updated: 2016-11-02

Related Papers

A randomized trial of the efficacy and safety of quilizumab in adults with inadequately controlled allergic asthma.

2016-03-1868 citations

Targeting membrane-expressed IgE B cell receptor with an antibody to the M1 prime epitope reduces IgE production

Science Translational Medicine2014-07-02121 citations